<DOC>
	<DOC>NCT00901732</DOC>
	<brief_summary>Patients who have been diagnosed with a head and/or neck cancer commonly develop oral mucositis (OM). The purpose of this study is to estimate the effect of Caphosol on OM and to evaluate if Caphosol had any effect on clinical outcomes which include quality of life, oral intake, swallowing function and pain.</brief_summary>
	<brief_title>Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Diagnosed Head and Neck Cancer patients with planned Radiation therapy Have at least one of 10 predefined anatomic mucosal subsites on view Age &gt;/= 18 years Life expectancy &gt;/= 6 months Planned RT to the head/neck Must be able to perform oral rinse Active infections of oral cavity physiologic condition that precludes the use of an oral rinse Hypersensitivity to Caphosol ingredients Presence of mucosal ulceration at baseline Poorly controlled hypertension, DM or other serious medical/psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Caphosol</keyword>
	<keyword>Oral Mucositis</keyword>
	<keyword>Eusa Pharma</keyword>
	<keyword>Moffitt Cancer Center</keyword>
</DOC>